The DOI matches its Crossref record; 242 of the 242 references it cites were found in a registry or an index; 29 of the 265 sources its claims cite were checked for support.
Vascular smooth muscle cells in atherosclerosis
Abstract
Vascular smooth muscle cells (VSMCs) are a major cell type present at all stages of an atherosclerotic plaque. According to the 'response to injury' and 'vulnerable plaque' hypotheses, contractile VSMCs recruited from the media undergo phenotypic conversion to proliferative synthetic cells that generate extracellular matrix to form the fibrous cap and hence stabilize plaques. However, lineage-tracing studies have highlighted flaws in the interpretation of former studies, revealing that these studies had underestimated both the content and functions of VSMCs in plaques and have thus challenged our view on the role of VSMCs in atherosclerosis. VSMCs are more plastic than previously recognized and can adopt alternative phenotypes, including phenotypes resembling foam cells, macrophages, mesenchymal stem cells and osteochondrogenic cells, which could contribute both positively and negatively to disease progression. In this Review, we present the evidence for VSMC plasticity and summarize the roles of VSMCs and VSMC-derived cells in atherosclerotic plaque development and progression. Correct attribution and spatiotemporal resolution of clinically beneficial and detrimental processes will underpin the success of any therapeutic intervention aimed at VSMCs and their derivatives.
Overview
CoChat Summary
TL;DR
This review argues that vascular smooth muscle cells (VSMCs) are a major source of plaque cells and extracellular matrix throughout atherosclerosis, with greater plasticity and clonality than previously recognized. Lineage-tracing studies show VSMC-derived cells adopt macrophage-like, foam cell, mesenchymal stem cell-like, and osteochondrogenic phenotypes, contributing both to plaque stability and instability.
Key findings
- In murine atherosclerosis, VSMCs generate 30–70% of all plaque cells; in mice they contribute 30–70% of macrophage marker-positive cells, while in humans around 30–40% of CD68-positive cells and 50% of foam cells are VSMC-derived.
- Plaque VSMC-derived cells arise by clonal expansion of relatively few medial VSMCs; most medial cells do not contribute to mouse plaque formation, and VSMC migration independent of proliferation is limited. Early cap VSMCs are highly proliferative and express αSMA, SMMHC, and PDGFRβ.
- VSMCs adopt multiple phenotypes: fibrous cap ECM-producing cells, macrophage-like/foam cells, Sca1+ mesenchymal stem cell-like cells, and Runx2/Cbfa1+ osteochondrogenic/chondrocyte-like cells. VSMC-specific KLF4 deletion reduces switching to macrophage marker-positive cells and increases fibrous cap thickness and αSMA-positive cell content.
- Human plaque VSMC telomeres are markedly shortened; one study reported more than 50% of all plaque cells to be senescent, with senescent cells appearing within 9 days of fat feeding, and genetic or pharmacological elimination of p16-positive cells reduced plaque formation and progression. Thin-cap fibroatheromas are defined by a fibrous cap of less than 65 µm; plaque rupture accounts for around 60–70% of thrombosis cases, erosion for most of the remainder, and calcified nodules for typically around 5%.
Methods
- Narrative review; no primary data, sample, or statistical analysis are reported.
- Synthesizes evidence from murine genetic lineage-tracing/fate-mapping studies, human autopsy and plaque histology, in vitro VSMC culture, and genetic association/functional genomics studies.
- Main analysis is qualitative synthesis, with tables and boxes summarizing lineage tracing, embryonic origins, molecular mechanisms, and cell death.
Limitations
- The paper states that extrapolating from mice to humans is difficult: diffuse intimal thickenings are absent in most animal models, fibroatheromas rarely rupture in mice, and an IL-1β-neutralizing antibody was deleterious to the fibrous cap in mice but beneficial in the human CANTOS trial.
- Proving effects of senescent VSMCs is hampered by technical difficulties in mice: telomeres are approximately 10 times longer than in humans, in vitro SASP studies are problematic, and p16/SAβG detection is difficult, especially because macrophages in plaques express these markers.
- The text also notes lacking definitive human evidence for anatomical segmentation of VSMC populations and for VSMCs as the source of fibrous cap ECM; as a review, conclusions await human single-cell/omics confirmation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 10 Not valid · 107 Not checked · 57 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lineage tracing studies have unambiguously demonstrated that VSMCs contribute substantially to plaque formation in murine models of atherosclerosis, generating 30-70% of all plaque cells 11,18-20,22,23 .”
What the sources say
- Partly supportedcites [11] Shankman, L. S. et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat. Med. 21, 628–637 (2015). sourceExperimental — accuracy not yet measured
Shankman et al. (2015) is itself a Myh11-CreERT2 lineage-tracing study in Apoe−/− mice and supports the low end of the attributed range: Results ('Most atherosclerotic plaque SMCs are not identified by ACTA2') report that phenotypically modulated SMCs (YFP+ACTA2−) comprised ~30% of total lesional cells, and the Discussion restates this as 'definitive evidence' that they 'comprise ~30% of the total cellular composition of the lesion'. No passage in our copy supports the upper bound of 70% of all plaque cells — the largest SMC-derived fractions reported are 30% Mϕ-like, 7% MSC-like, 12% MF-like and 32–51% of unknown phenotype (Results, 'SMCs within atherosclerotic plaques express markers of Mϕs, MSCs, and MFs'), 36% of LGALS3+ cells being YFP+, and up to 45% of aortic MSC-like cells YFP+ (with the caveat that these may include adventitial cells rather than lesional cells). The 'unambiguous' framing also overstates the paper, which repeatedly stresses residual uncertainty (Introduction: 'we still do not know which cells within lesions are SMC-derived and to what extent they contribute'; and for the 45% MSC figure, 'it is unclear if all of these are located within lesions'). (LLM, conf=0.78)
- Partly supportedcites [18] Gomez, D., Shankman, L. S., Nguyen, A. T. & Owens, G. K. Detection of histone modifications at specific gene loci in single cells in histological sections. Nat. Methods 10, 171–177 (2013). This paper and those of Feil et al. (2014) and Shankman et al. (2015) are the first lineage-tracing studies of VSMCs in the context of atherosclerosis. sourceExperimental — accuracy not yet measured
Our copy does perform and report SMC lineage tracing in a murine atherosclerosis model (SMC-eYFP+/+ ApoE−/−, Western diet 18 weeks, brachiocephalic arteries), and the Results (p. ~4) state 'large numbers of phenotypically modulated SMCs within lesions' identifiable only via the eYFP lineage tracer — supporting that lineage tracing shows VSMCs contribute to plaques in mice. However, no passage states the magnitude attributed here: the paper's only lesion percentages are that >95% of SMC-derived lesion cells were undetectable by ACTA2/MYH11 and that >95% of medial cells were YFP+, not that SMCs generate 30-70% of all plaque cells. The Discussion (p. ~6) likewise says marker-based studies 'grossly under-estimated the frequency of SMCs within lesions' without giving a quantitative contribution. The 30-70% range is therefore unsupported by this source (it is one of several citations pooled in the citing sentence). (LLM, conf=0.72)
- Partly supportedcites [19] Albarrán-Juárez, J., Kaur, H., Grimm, M., Offermanns, S. & Wettschureck, N. Lineage tracing of cells involved in atherosclerosis. Atherosclerosis 251, 445–453 (2016). sourceExperimental — accuracy not yet measured
Albarrán-Juárez et al. (2016) is indeed a murine lineage-tracing (fate-mapping) study showing that VSMCs contribute to plaque cells: the Abstract and Experimental results report 16% of CD68+ plaque cells as SM-derived and that the majority of aSMA+ plaque cells were EGFP+, and the Discussion (Sec. 4) states 'our analyses in SM reporter mice provide clear evidence for a role of VSMC transdifferentiation'. However, no passage in our copy reports the attributed magnitude that VSMCs generate 30-70% of ALL plaque cells — every percentage in the paper is relative to a marker-defined subset (16% of CD68+ cells, 31% of aSMA+ cells non-SM-derived, 40% of CD68+ cells EGFP-negative, 70% of SM-derived cells having lost aSMA), and the Introduction explicitly notes that low labelling efficiency in an earlier study 'precluded a quantitative assessment of the overall contribution of these cells to atherosclerotic lesions'. The claim's 'unambiguously demonstrated' also overstates this source, which frames the field as containing 'substantial ambiguity' and says previous VSMC-transdifferentiation data 'remain controversial'. (LLM, conf=0.75)
- Partly supportedcites [20] Chappell, J. et al. Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells contributes to neointimal formation in mouse injury and atherosclerosis models. Circ. Res. 119, 1313–1323 (2016). This article demonstrates that different VSMC phenotypes arise from the same ancestral cell in atherosclerosis. sourceExperimental — accuracy not yet measured
The Abstract states that lineage-tracing experiments have 'convincingly shown' VSMC phenotypic switching in vivo and that VSMC-derived cells 'contribute substantially to the generation of the plaque core' in mouse models of atherosclerosis, and the Results section 'Clonal Expansion of Few VSMCs in Atherosclerotic Plaques' reports the paper's own quantification: on average 70% of plaque cells were Confetti+ (VSMC-derived), ranging from 40% to 90%. So the qualitative claim (substantial VSMC contribution in murine atherosclerosis) is fully supported, and 70% sits at the top of the cited 30-70% range. However, the 30% lower bound is not this paper's figure for total VSMC contribution — the only ≈30% value in our copy ('Generation of Phenotypically Distinct Cells From VSMCs') refers to a previous study's estimate of phenotypically modulated VSMC-derived cells as a subset of plaque cells, while this paper's own minimum is 40% and its maximum 90%. The claim's range therefore overstates/understates the source's bounds in both directions. (LLM, conf=0.72)
- Partly supportedcites [22] Jacobsen, K. et al. Diverse cellular architecture of atherosclerotic plaque derives from clonal expansion of a few medial SMCs. JCI Insight 2, 95890 (2017). sourceExperimental — accuracy not yet measured
Our copy of Jacobsen et al. (2017) is indeed a murine lineage-tracing study (Myh11-CreER^T2 Confetti plus Apoe-/- aggregation chimeras) and it supports the qualitative half of the claim: the Discussion and 'Different plaque SMC phenotypes' sections speak of 'the total abundance of the SMC lineage in atherosclerotic plaques' and of SMC proliferation as 'the quantitatively dominant mechanisms underlying SMC accumulation in atherosclerosis'. However, the specific magnitude attributed — VSMCs generating 30-70% of all plaque cells — is not stated anywhere in our copy: the quantitative readouts reported are numbers of SMC patches, ~2,500 plaque SMC profiles, recombination efficiencies (56.3% of medial SMCs; 30.5% RFP, 9.0% mCFP) and estimates of founder medial SMCs per plaque (2.1, 10.2, 11.6 at 12, 24, 36 weeks; 'Recruitment of plaque SMCs'). Searches for a percentage of total plaque nuclei/cells of SMC lineage returned no such figure, so the 30-70% range (a pooled value across the sentence's several citations) is not attributable to this source. (LLM, conf=0.70)
- Partly supportedcites [23] Misra, A. et al. Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells. Nat. Commun. 9, 2073 (2018). This article provides evidence that secreted factors affect VSMC clonality in atherosclerosis. sourceExperimental — accuracy not yet measured
Misra et al. (2018) is indeed a murine SMC lineage-tracing (fate-mapping) study and it supports the 'contribute substantially' part: Results 'Most atherosclerotic plaque cells derive from one progenitor' states that with increasing high-fat-diet duration labeled cells constituted a higher percentage of total aortic plaque cells, 'remarkably, 57 ± 7% by 16 weeks', and the Discussion repeats that a single SMC gives rise to cells 'which comprise the majority of the total cells in an advanced plaque' (Fig. 2d quantifies percent SMC-derived across 6, 12 and 16 weeks). However, our copy nowhere states the 30–70% range attributed here: the only explicit value is 57 ± 7% at 16 weeks, and the low end (30%) and high end (70%) of the quoted interval are not reported by this paper (the 82% figure it mentions belongs to Shankman et al. and refers to the fraction of SMC-derived cells assuming SMA− fates, not to the fraction of plaque cells that are SMC-derived). So the range is a synthesis of the several citations in the citing sentence, of which this source supplies only one interior data point. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“VSMC-derived cells that express mesenchymal stem cell markers (in particular Sca1) have also been identified in the healthy media 43 and in plaques 11,43 , and may represent a plastic intermediate population that is readily responsive to inflammation and capable of generating contractile or phenotypically switched VSMCs 43 .”
What the sources say
- Not checked yetcites [43] Dobnikar, L. et al. Disease-relevant transcriptional signatures identified in individual smooth muscle cells from healthy mouse vessels. Nat. Commun. 9, 4567 (2018).
- Supportedcites [11] Shankman, L. S. et al. KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat. Med. 21, 628–637 (2015). source
The Results section reports SMC-derived cells within atherosclerotic lesions that express the mesenchymal stem cell marker SCA1. In the citing sentence, this source is cited for the finding in plaques; the healthy-media finding is cited to a different source. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This study reported more than 50% of all plaque cells to be senescent, including VSMCs, macrophages and endothelial cells 84 .”
What the sources say
- Partly supportedcites [84] Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472–477 (2016). This article demonstrates the effect of senescence in atherosclerosis. sourceExperimental — accuracy not yet measured
Our copy supports the compositional half of the claim: the Fig. 1A passage reports that TEM of plaques revealed three morphologically distinct senescent cell types producing X-Gal crystals — elongated vacuolated cells in the endothelial layer, spindly foam cells with VSMC properties, and large foamy cells resembling lipid-loaded macrophages (and the discussion echoes 'advanced plaques contain three morphologically distinct senescent cell types'). However, the paper explicitly labels these as endothelial-like, foamy VSMC–like and foamy macrophage–like because plaquy cells change shape and lineage markers, 'precluding accurate assessment of cell origin', so the claim's flat assignment to VSMCs/macrophages/endothelial cells overstates the source. No passage in our copy (searched: '>50% of plaque cells senescent', 'proportion/percentage of neointimal cells positive for senescence markers', 'X-Gal crystals quantified as fraction of total plaque cells', 'half of the cells') states that more than 50% of all plaque cells are senescent; the only quantitative figures are plaque-burden changes (~60% lower with GCV). The quantitative core of the claim is therefore unverified, and the study is in Ldlr−/− mice, not stated as human plaque. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Senescence is a protective mechanism that induces cell cycle arrest to prevent transmission of defects to progeny cells, particularly to stop malignant transformation 72-74 .”
What the sources say
- Not checked yetcites [72] Munoz-Espin, D. & Serrano, M. Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014). source
- Supportedcites [73] Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75, 685–705 (2013). source
The Cellular Senescence: Overview section describes senescence as an essentially irreversible arrest of cell proliferation in response to potentially oncogenic stress and calls that arrest a formidable barrier to malignant tumorigenesis. Preventing defects from being passed to progeny cells is a reasonable paraphrase of this growth arrest; the copy does not use those exact words. No page number is available in the supplied copy. (LLM, conf=0.90)
- Supportedcites [74] Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of senescence. Genes Dev. 24, 2463–2479 (2010). source
In “Cellular senescence as a pathophysiological phenomenon” (page not provided), the paper describes oncogene-induced senescence as a defense against tumor formation: a cell with an oncogenic lesion withdraws from the proliferative pool. This supports the claim that arrest prevents the affected cell from producing progeny and progressing toward malignancy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ECM has a central role in initiation of atherosclerosis, primarily through the interaction between the negatively charged side chains of proteoglycans (particularly chondroitin sulphate of biglycan and versican and heparin sulphate of perlecan 110 ) with positively charged apolipoproteins (especially apolipoprotein B) , which leads to the retention of plasma-derived lipoproteins 101,111 - as”
What the sources say
- Not checked yetcites [110] Tran-Lundmark, K. et al. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ. Res. 103, 43–52 (2008).
- Not checked yetcites [101] Skalen, K. et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417, 750–754 (2002). source
- Not checked yetcites [111] Smith, E. B. & Slater, R. S. The microdissection of large atherosclerotic plaques to give morphologically and topographically defined fractions for analysis. 1. The lipids in the isolated fractions. Atherosclerosis 15, 37–56 (1972). source
- Not checked yetcites [112] Tabas, I., Williams, K. J. & Borén, J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 116, 1832–1844 (2007). source
- Partly supportedcites [113] Williams, K. J. & Tabas, I. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 551–561 (1995). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
80 more claims · 6 with their cited sources checked
Create a free account to see all 188 claims and to verify the 236 references still open.
- It may state two separate claims as one. 82
- Probably not a substantial claim. 27
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Plasticity of VSMCs · p. 4
“These results support the hypothesis proposed by Wissler in 1968 62 that at least a subset of foam cells are VSMCderived.”
§ References · p. 28
“62. Wissler, R. W. The arterial medial cell, smooth muscle, or multifunctional mesenchyme? Circulation 36, 1-4 (1967).”
Citations
Cites
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A., & Schwartz, S. M. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.5.1262 · Cited by 4,084
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Davies, M. J., & Thomas, A. C. (1985) · Heart · doi:10.1136/hrt.53.4.363 · Cited by 1,985
Cited by
NF-κB in biology and targeted therapy: new insights and translational implications
Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01757-9 · Cited by 2,047
Atherosclerosis: Recent developments
Björkegren, J. L. M., & Lusis, A. J. (2022) · Cell · doi:10.1016/j.cell.2022.04.004 · Cited by 1,249
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“Although the prevailing point is that VSMCs exert beneficial roles in advanced atherosclerosis as they can stabilize fibrous cap and are major cells producing ECM, single-cell RNA-sequencing combination with lineage tracing have revealed much morediverse phenotypes of VSMCs in the various stages of atherosclerosis.(1,…”
BackgroundTargeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
Pan, H., Xue, C., Auerbach, B. J., Fan, J., Bashore, A. C., Cui, J., Yang, D. Y., Trignano, S. B., Liu, W., Shi, J., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048378 · Cited by 616
Metadata
- Authors
- Basatemur, G. L., Jørgensen, H. F., Clarke, M. C. H., Bennett, M. R., & Mallat, Z.
- Affiliations
- University of Cambridge (GB)
- Inserm (FR)
- Corresponding author
- Mallat, Ziad
- Venue
- Nature Reviews Cardiology
- Published
- 2019-06-26
- Volume
- 16
- Issue
- 12
- Pages
- 727-744
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W2955108563
- Semantic Scholar
- 8089476f497703722ceefa7d7efc0c2292f1b75e
- Cited by
- 1,099
- References
- 242
- Citations by year
- 2026: 118 · 2025: 193 · 2024: 175 · 2023: 140 · 2022: 201 · 2021: 158 · 2020: 100 · 2019: 12
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- British Heart Foundation (PG/13/25/30014, PG/16/11/32021, PG/19/6/34153, FS/13/3/30038, PG/12/86/29930, PG/16/63/32307, FS/18/19/33371, RG/13/14/30314, FS/13/29/30024, FS/15/38/31516, FS/09/005/26845, FS/18/56/34177A, PG/17/9/32834, RG/16/8/32388, PG/11/112/29272)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- vascular smooth muscle cells, atherosclerosis, response-to-injury hypothesis, extracellular matrix, lineage tracing, clonal expansion, foam cells, macrophage-like cells, mesenchymal stem cells, osteochondrogenic differentiation
- MeSH terms
- Cell Plasticity, Animals, Extracellular Matrix, Humans, Phenotype, Cellular Senescence, Disease Progression, Myocytes, Smooth Muscle, Cell Proliferation, Atherosclerosis, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular smooth muscle cells in atherosclerosis. https://app.cochat.ai/papers/10.1038/s41569-019-0227-9
- The paper
- Basatemur, G. L., Jørgensen, H. F., Clarke, M. C. H., Bennett, M. R., & Mallat, Z. (2019). Vascular smooth muscle cells in atherosclerosis. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-019-0227-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.